Isabel RodrÃ-guez-Barraquer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/853668/publications.pdf

Version: 2024-02-01

80 papers 5,207 citations

33 h-index 110387 64 g-index

109 all docs

109 docs citations

109 times ranked 9633 citing authors

#	Article	IF	CITATIONS
1	Risk factor targeting for vaccine prioritization during the COVID-19 pandemic. Scientific Reports, 2022, 12, 3055.	3.3	19
2	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases, 2022, 9, ofab640.	0.9	56
3	COVID-19 Vaccination and Estimated Public Health Impact in California. JAMA Network Open, 2022, 5, e228526.	5. 9	15
4	TNF-α+ CD4+ TÂcells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Reports Medicine, 2022, 3, 100640.	6.5	15
5	Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. Nature Communications, 2022, 13, 2451.	12.8	6
6	Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand. PLoS Pathogens, 2022, 18, e1010500.	4.7	5
7	Assessing the role of multiple mechanisms increasing the age of dengue cases in Thailand. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2115790119.	7.1	16
8	Genetic variation that determines <i>TAPBP </i> expression levels associates with the course of malaria in an HLA allotype-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	3
9	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells, 2021, 10, 386.	4.1	125
10	Withinâ€household clustering of genetically related Plasmodium falciparum infections in a moderate transmission area of Uganda. Malaria Journal, 2021, 20, 68.	2.3	4
11	HLA Alleles B*53:01 and C*06:02 Are Associated With Higher Risk of P. falciparum Parasitemia in a Cohort in Uganda. Frontiers in Immunology, 2021, 12, 650028.	4.8	9
12	Age-Related Changes in Malaria Clinical Phenotypes During Infancy Are Modified by Sickle Cell Trait. Clinical Infectious Diseases, 2021, 73, 1887-1895.	5 . 8	4
13	The impact of stopping and starting indoor residual spraying on malaria burden in Uganda. Nature Communications, 2021, 12, 2635.	12.8	37
14	Comparison of infection control strategies to reduce COVID-19 outbreaks in homeless shelters in the United States: a simulation study. BMC Medicine, 2021, 19, 116.	5 . 5	18
15	Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. Nature Medicine, 2021, 27, 1395-1400.	30.7	21
16	Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. Lancet Infectious Diseases, The, 2021, 21, 1568-1578.	9.1	90
17	Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study. Lancet Infectious Diseases, The, 2021, 21, 929-938.	9.1	46
18	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	10.3	117

#	Article	IF	CITATIONS
19	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Reports, 2021, 36, 109518.	6.4	142
20	Trade-offs between individual and ensemble forecasts of an emerging infectious disease. Nature Communications, 2021, 12, 5379.	12.8	16
21	Association of Inhibitory Killer Cell Immunoglobulin-like Receptor Ligands With Higher <i>Plasmodium falciparum </i> Parasite Prevalence. Journal of Infectious Diseases, 2021, 224, 175-183.	4.0	7
22	Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. Open Forum Infectious Diseases, 2021, 8, ofaa531.	0.9	9
23	The Impact of Multiple Rounds of Indoor Residual Spraying on Malaria Incidence and Hemoglobin Levels in a High-Transmission Setting. Journal of Infectious Diseases, 2020, 221, 304-312.	4.0	14
24	Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?. Journal of Infectious Diseases, 2020, 222, 1772-1775.	4.0	81
25	A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nature Communications, 2020, 11, 4704.	12.8	775
26	Estimating malaria incidence from routine health facility-based surveillance data in Uganda. Malaria Journal, 2020, 19, 445.	2.3	11
27	Influenza, Varicella, and Mumps Outbreaks in US Migrant Detention Centers. JAMA - Journal of the American Medical Association, 2020, 325, 180-182.	7.4	10
28	Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Science Immunology, 2020, 5, .	11.9	138
29	Associations between red blood cell variants and malaria among children and adults from three areas of Uganda: a prospective cohort study. Malaria Journal, 2020, 19, 21.	2.3	8
30	Mapping global variation in dengue transmission intensity. Science Translational Medicine, 2020, 12, .	12.4	131
31	Rapid shifts in the age-specific burden of malaria following successful control interventions in four regions of Uganda. Malaria Journal, 2020, 19, 128.	2.3	21
32	The Impact of Control Interventions on Malaria Burden in Young Children in a Historically High-Transmission District of Uganda: A Pooled Analysis of Cohort Studies from 2007 to 2018. American Journal of Tropical Medicine and Hygiene, 2020, 103, 785-792.	1.4	14
33	Malaria Transmission, Infection, and Disease following Sustained Indoor Residual Spraying of Insecticide in Tororo, Uganda. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1525-1533.	1.4	43
34	Sex-based differences in clearance of chronic Plasmodium falciparum infection. ELife, 2020, 9, .	6.0	46
35	Serological inference of past primary and secondary dengue infection: implications for vaccination. Journal of the Royal Society Interface, 2019, 16, 20190207.	3.4	12
36	Pareto rules for malaria super-spreaders and super-spreading. Nature Communications, 2019, 10, 3939.	12.8	47

#	Article	IF	CITATIONS
37	Heterogeneous local dynamics revealed by classification analysis of spatially disaggregated time series data. Epidemics, 2019, 29, 100357.	3.0	9
38	Dengue pre-vaccination screening and positive predictive values. Lancet Infectious Diseases, The, 2019, 19, 132-134.	9.1	18
39	Impact of Microscopic and Submicroscopic Parasitemia During Pregnancy on Placental Malaria in a High-Transmission Setting in Uganda. Journal of Infectious Diseases, 2019, 220, 457-466.	4.0	18
40	Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science, 2019, 363, 607-610.	12.6	202
41	Long-term circulation of Zika virus in Thailand: an observational study. Lancet Infectious Diseases, The, 2019, 19, 439-446.	9.1	92
42	Impacts of Zika emergence in Latin America on endemic dengue transmission. Nature Communications, 2019, 10, 5730.	12.8	48
43	Persistent Parasitemia Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual Spraying in Tororo, Uganda. Journal of Infectious Diseases, 2019, 219, 1104-1111.	4.0	22
44	Nationally-representative serostudy of dengue in Bangladesh allows generalizable disease burden estimates. ELife, 2019, 8, .	6.0	58
45	Opportunities for improved surveillance and control of dengue from age-specific case data. ELife, 2019, 8, .	6.0	30
46	Spatiotemporal incidence of Zika and associated environmental drivers for the 2015-2016 epidemic in Colombia. Scientific Data, 2018, 5, 180073.	5.3	29
47	Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10762-10767.	7.1	26
48	Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. PLoS Neglected Tropical Diseases, 2018, 12, e0006862.	3.0	93
49	Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature, 2018, 557, 719-723.	27.8	213
50	Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Medicine, 2018, 15, e1002606.	8.4	21
51	Heterogeneous exposure and hotspots for malaria vectors at three study sites in Uganda. Gates Open Research, 2018, 2, 32.	1.1	17
52	Taking Sharper Pictures of Malaria with CAMERAs: Combined Antibodies to Measure Exposure Recency Assays. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1120-1127.	1.4	24
53	Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. ELife, 2018, 7, .	6.0	100
54	Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 2017, 35, 4659-4669.	3.8	81

#	Article	IF	CITATIONS
55	Impact of interventions and the incidence of ebola virus disease in Liberiaâ€"implications for future epidemics. Health Policy and Planning, 2017, 32, 205-214.	2.7	45
56	High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1296-1301.	1.4	19
57	Viral Epidemiology. , 2016, , 241-252.		4
58	The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Medicine, 2016, 13, e1002181.	8.4	178
59	Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science, 2016, 353, 1033-1036.	12.6	195
60	Trends in the Mechanistic and Dynamic Modeling of Infectious Diseases. Current Epidemiology Reports, 2016, 3, 212-222.	2.4	27
61	Assessing the global threat from Zika virus. Science, 2016, 353, aaf8160.	12.6	311
62	Quantifying Heterogeneous Malaria Exposure and Clinical Protection in a Cohort of Ugandan Children. Journal of Infectious Diseases, 2016, 214, 1072-1080.	4.0	28
63	Dependability of results in conference abstracts of randomized controlled trials in ophthalmology and author financial conflicts of interest as a factor associated with full publication. Trials, 2016, 17, 213.	1.6	29
64	Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection. Journal of Infectious Diseases, 2016, 213, 1428-1435.	4.0	36
65	Reconstruction of 60 Years of Chikungunya Epidemiology in the Philippines Demonstrates Episodic and Focal Transmission. Journal of Infectious Diseases, 2016, 213, 604-610.	4.0	72
66	Enhancing disease surveillance with novel data streams: challenges and opportunities. EPJ Data Science, 2015, 4, .	2.8	119
67	Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum. Malaria Journal, 2015, 14, 150.	2.3	18
68	Differential efficacy of dengue vaccine by immune status. Lancet, The, 2015, 385, 1726.	13.7	13
69	The Hidden Burden of Dengue and Chikungunya in Chennai, India. PLoS Neglected Tropical Diseases, 2015, 9, e0003906.	3.0	65
70	Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia. PLoS Neglected Tropical Diseases, 2014, 8, e2871.	3.0	59
71	Variability in Dengue Titer Estimates from Plaque Reduction Neutralization Tests Poses a Challenge to Epidemiological Studies and Vaccine Development. PLoS Neglected Tropical Diseases, 2014, 8, e2952.	3.0	46
72	Revisiting Rayong: Shifting Seroprofiles of Dengue in Thailand and Their Implications for Transmission and Control. American Journal of Epidemiology, 2014, 179, 353-360.	3.4	76

#	Article	IF	CITATIONS
73	Potential opportunities and perils of imperfect dengue vaccines. Vaccine, 2014, 32, 514-520.	3.8	34
74	Challenges in the Interpretation of Dengue Vaccine Trial Results. PLoS Neglected Tropical Diseases, 2013, 7, e2126.	3.0	22
75	Noninferiority of Miltefosine Versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children. Journal of Infectious Diseases, 2012, 205, 684-692.	4.0	77
76	Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC Infectious Diseases, 2012, 12, 233.	2.9	54
77	From Re-Emergence to Hyperendemicity: The Natural History of the Dengue Epidemic in Brazil. PLoS Neglected Tropical Diseases, 2011, 5, e935.	3.0	125
78	Etiologic Agent of an Epidemic of Cutaneous Leishmaniasis in Tolima, Colombia. American Journal of Tropical Medicine and Hygiene, 2008, 78, 276-282.	1.4	36
79	Etiologic agent of an epidemic of cutaneous leishmaniasis in Tolima, Colombia. American Journal of Tropical Medicine and Hygiene, 2008, 78, 276-82.	1.4	19
80	Predicting intensities of Zika infection and microcephaly using transmission intensities of other arboviruses. Bulletin of the World Health Organization, 0, , .	3.3	0